Sunitinib Malate

Licensed by Pfizer Catalog No.S1042

Sunitinib Malate Chemical Structure

Molecular Weight(MW): 532.56

Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 97 In stock
USD 147 In stock
USD 447 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 42 Publications

12 Customer Reviews

  • PDGF-AA induces Ezh2 expression and proliferation in juvenile islets but not in adult islets. Western immunoblots of indicated islet proteins from 3 week or 9 month-old WT islets 2 days after exposure to PDGF-AA alone, or PDGF-AA plus RTK inhibitors Sunitinib.

    Nature 2011 478(7369):349-55. Sunitinib Malate purchased from Selleck.

    Assessment of effects on human juvenile or adult islets after exposure to PDGF-AA (50 ng/ml) for 2 days, with or without Sunitinib (2 uM) or U0126 (10 uM)co-treatment. Average percentage of BrdU+ insulin+ cells was morphometry from sectioned islets immunostained for insulin (green), glucagon (white) and BrdU (red). n = 3-6 independent experiments.

    Nature 2011 478(7369):349-55. Sunitinib Malate purchased from Selleck.

  • Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Sunitinib Malate purchased from Selleck.

    A, Tumor growth curves from the initial sunitinib drug trials, with endpoint set at 1,300 mm3 (mean ± SEM). Measurements began one week after tumor inoculation and on the day sunitinib treatment began. Subsequent experimental endpoints were set on the basis of these growth curves and their intersections with this data are shown. B, Histogram plot showing the distribution of tumor sizes at day 8 of treatment. Sunitinib-treated tumors exceeding 250 mm3 in size were identified as falling into the nonresponsive cohort. Sunitinib treatment significantly retards growth of responsive tumors.

    Cancer Res, 2017, 77(4):1008-1020 . Sunitinib Malate purchased from Selleck.

  • Sunitinib decreases FLT-3 and RET phosphor ylation but increases ERK phosphorylation in a time-dependent manner. H295R and SW13 cells were treated with sunitinib (10 nM) for various time points as indi-cated. Cell lysates were prepared and phospho-FLT-3, RET, and ERK levels were monitored by Western Blot-ting. Re-probing against FLT-3, RET, and ERK was done to ensure equal protein loading.

    Surgery 2012 152, 1045-50. Sunitinib Malate purchased from Selleck.

    Sunitinib or PD98059 decreases cell proliferation in a dose-dependent manner. H295R and SW13 cells were treated with various concentration of sunitinib or PD98059 for 48 hours as indicated. Treated cells were subjected to the MTS proliferation assay. Similar experiments were repeated 3 times. Histograms represent relative % of OD490 nm absorbance (* P < .05). All data are relative multiples of expression compared with untreated cells. The data are representative of three experiments and are expressed as the mean ?SE.

    Surgery 2012 152, 1045-50. Sunitinib Malate purchased from Selleck.

  • Autophagic activation in sunitinib- and sorafenib- but not AZD6244-treated cells. Medullary thyroid cancer-1.1 (MTC-1.1; A) and TT ( B) cells were treated with dimethyl sulfoxide (DMSO), sunitinib (50 nM), sorafenib (10 nM), AZD6244 (30 nM), or everolimus (20 nM) for 48 hours. Cell lysates were prepared, and light chain 3 (LC3)-I and -II cleaved caspase-3 protein levels were monitored by Western blotting. Reprobing against actin was per formed to ensure equal protein loading. ( C ) MTC-1.1 and TT cells were transiently transfected with autophagy protein 5 (Atg-5) small inter fering RNA. Transfection with scrambled small inter fering RNA was used as a control. After transfection, cells with and without Atg-5 knockdown were exposed to DMSO or 20 nM of everolimus for 48 hours. Cell lysates were pre- pared and LC3-I and -II protein expression levels were monitored by Western blotting. Reprobing against Atg-5 was per formed to monitor Atg-5 knockdown efficiency. Reprobing against actin was per formed to ensure equal protein.

    Surgery 2012 152, 1142-9. Sunitinib Malate purchased from Selleck.

    Autophagy inhibition blocks the antiproliferative effects of sunitinib and sorafenib but not AZD6244. Medullary thyroid cancer–1.1 (MTC-1.1) and TT cells were transfected transiently with scrambled or autophagy protein 5 (Atg-5) small inter fering RNA. After transfection, cells with and without Atg-5 knockdown were exposed to sunitinib (50 nM), sorafenib (10 nM), and AZD6244 (30 nM) for 48 hours. Treated cells were subjected to a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium proliferation assay. Similar experiments were repeated 3 times. Histograms represent the relative percent of OD490 nM absorbance. The asterisk indicates significance versus scrambled small inter fering RNA–treated control ( P < .05). All data are relative multiples of expression compared to untreated cells. The data are representative of 3 experiments and are expressed as the mean ± the standard error.

    Surgery 2012 152, 1142-9. Sunitinib Malate purchased from Selleck.

  • Sunitinib limits the colonial growth of HT-29 by downregulating HIF-1a. (A) The number and size of colonies formed in soft agar. The numbers of small colonies (<50 μm diameter) were not different among conditions of a serial concentration of sunitinib. On the contrary, large colonies (>50 μm diameter) disappeared after incubation with sunitinib. Each point represents the mean and SD from four separate experiments. (B) HIF-1a expression and hypoxia within HT-29 colony. After colonies grew for 4 weeks, HIF-1a and hypoxia were visualized by immunofluoroscence staining. Bar = 20 μm.

    Biochem Bioph Res Co 2010 398, 205–211. Sunitinib Malate purchased from Selleck.

    2. Sunitinib downregulates HIF-1a. (A) Dose-dependent repression of HIF-1a protein level by sunitinib in HT-29. HT-29 cells were incubated under normoxic (N) or hypoxic (H) conditions in the presence of sunitinib for 24 h. HIF-1a and ARNT proteins in total cell lysates were analyzed by Western blotting. (B) Sunitinib attenuates the hypoxic induction of HIF-1 target genes. RNAs were isolated from HT-29 cells subjected to normoxia (N) or hypoxia (H) in the presence of sunitinib for 16 h. The mRNAs of HIF-1a and its target genes were analyzed by RT-PCR and autoradiography. PGK1 indicates phosphoglycerate kinase 1; PDK1, pyruvate dyhydrogenase kinase 1; CAIX, carbonic anhydrase IX. (C) Sunitinib-induced HIF-1 inhibition. Epo-enhancer and b- galactosidase reporter plasmids were co-transfected into HEK293 cells. After 16 h incubation, luciferase and b-galactosidase activities were measured. *P < .05 versus the hypoxic control.

     

     

    Biochem Bioph Res Co 2010 398, 205–211. Sunitinib Malate purchased from Selleck.

  • Sunitinib inhibits 50-UTR-dependent translation of HIF-1a. (A) 50 cap-dependent translational activity of HIF-1a. The luciferase reporter plasmid contains the HIF-1a 50-UTR segment between the tk promoter and the luciferase gene. HT-29 cells were co-transfected with the reporter plasmid (8 lg per 100-mm dish) and the b-gal plasmid (4 μg). After 16 h incubation under normoxic or hypoxic conditions with sunitinib, cells were lysed and subjected to luciferase assay. *P < .05 versus the hypoxic control. (B) IRES-dependent translational activity of HIF-1a. The luciferase reporter plasmid contains the HIF-1a 50-UTR segment between the GFP gene and the luciferase gene. HT-29 cells were co-transfected with the reporter plasmid (8 μg) and the b-gal plasmid (4 μg). *P < .05 versus the hypoxic control. (C) Sunitinib inhibits phosphorylation of Akt. After 8 h incubation under hypoxic condition with sunitinib, HT-29 cells were lysed and subjected to Western blotting. (D) Sunitinib suppresses HIF-1a in VHL-null RCC4 cells. VHL (-/-) RCC4 cells were incubated under normoxic conditions sunitinib for 8 h, and HIF-1a in total cell lysates was analyzed by Western blotting.

     

     

    Biochem Bioph Res Co 2010 398, 205–211. Sunitinib Malate purchased from Selleck.

    Experimental layout for VEGF signaling blocking and LCMV infection in WT mice. Mice received two injections on day 0 and 3 p.i. of Abs as described in Material and Methods, or daily gavage of the VEGFR/PDGFR-inhibitor sunitinib. Inguinal LN volume on day 0 (D0) or day 8 (D8) p.i. after treatment of mice with control Ig or anti-VEGFR2, anti-VEGF-A Abs or sunitinib. Pooled from 1-2 independent experiments with 3-5 mice per treatment. D. Total HEV length on day 0 (D0) or day 8 (D8) p.i. as in C. No significant difference was found in C and D between day 8 control Ig and Ab- or inhibitor-treated values (One-way ANOVA).

    AACR Sunitinib Malate purchased from Selleck.

Purity & Quality Control

Choose Selective PDGFR Inhibitors

Biological Activity

Description Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit.
Targets
Kit [1]
(Cell-free assay)
FLT3 [1]
(Cell-free assay)
PDGFRβ [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
FGFR1 [1]
(Cell-free assay)
2 nM 80 nM 2.9 μM
In vitro

Sunitinib also potently inhibits Kit and FLT-3. [1] Sunitinib is a potent ATP-competitive inhibitor of VEGFR2 (Flk1) and PDGFRβ with Ki of 9 nM and 8 nM, respectively, displaying >10-fold higher selectivity for VEGFR2 and PDGFR than FGFR-1, EGFR, Cdk2, Met, IGFR-1, Abl, and src. In serum-starved NIH-3T3 cells expressing VEGFR2 or PDGFRβ, Sunitinib inhibits VEGF-dependent VEGFR2 phosphorylation and PDGF-dependent PDGFRβ phosphorylation with IC50 of 10 nM and 10 nM, respectively. Sunitinib inhibits VEGF-induced proliferation of serum-starved HUVECs with IC50 of 40 nM, and inhibits PDGF-induced proliferation of NIH-3T3 cells overexpressing PDGFRβ or PDGFRα with IC50 of 39 nM and 69 nM, respectively. [2] Sunitinib inhibits phosphorylation of wild-type FLT3, FLT3-ITD, and FLT3-Asp835 with IC50 of 250 nM, 50 nM, and 30 nM, respectively. Sunitinib inhibits the proliferation of MV4;11 and OC1-AML5 cells with IC50 of 8 nM and 14 nM, respectively, and induces apoptosis in a dose-dependent manner. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
3T3 M33IOGtqdmG|ZTDBd5NigQ>? NVjTSXQzUW6qaXLpeIlwdiCxZjDQSGdHNWmwZIXj[YQhSnKmVTDpcoNwenCxcnH0bY9vKHerdHigTWM2OCCxZjCwMlAxPyEQvF2= NV3LeXVMOTJ4NE[wNVk>
3T3 MoPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfnco9{UW6qaXLpeIlwdiCxZjDQcIF1\WyndD3k[ZJqfmWmIHfyc5d1cCCoYXP0c5IhcW6mdXPl[EA{XDNiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjBzIN88US=> NEXqTnYyOjZ2NkCxPS=>
3T3 NET2dnpHfW6ldHnvckBCe3OjeR?= MoXyTY5pcWKrdHnvckBw\iCYYYPjeYxieiCnbnTveIhmdGmjbDDndo94fGhiZnHjeI9zKHKnY3XweI9zKHerdHigTWM2OCCxZjCwMlA2KM7:TR?= NIXZRoMyOjZ2NkCxPS=>
3T3 M4WwOWtqdmG|ZTDBd5NigQ>? MWKyNEBucW5? MkDlSG1UVw>? NWDJWWpnS2WubIXsZZIhcW6qaXLpeIlwdiCxZjDWSWdHKGmwZIXj[YQhcHWvYX6gT2RTKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNlIh|ryP M2jYRlE3OTZ{MEC4
NIH3T3 NF\JeHdMcW6jc3WgRZN{[Xl? Mo\yNlAhdWmw Mnv0SG1UVw>? NW\aWmd5cW6qaXLpeEBpfW2jbjDLSHIhc2mwYYPlJIV5eHKnc4Pl[EB4cXSqIFnDOVAhd2ZiMD6wNVgh|ryP M4TPPFE3OTZ{MEC4
A549 NYHYTGtTTnWwY4Tpc44hSXO|YYm= MlXaSG1UVw>? NHH5bI5KdmirYnn0bY9vKG:oIHOtUYV1KGSncHXu[IVvfCCKR1[tbY5lfWOnZDDoeY1idiCDNUS5JINmdGxibXnndoF1cW:wIIfpeIghUUN3MDDv[kAzKM7:TR?= NX:2TldHOTh2M{SxOFU>
DU145 MkDYSpVv[3Srb36gRZN{[Xl? MnfTSG1UVw>? M3TTd2lvcGmkaYTpc44hd2ZiYz3N[ZQh\GWyZX7k[Y51KEiJRj3pcoR2[2WmIHj1cYFvKESXMUS1JINmdGxic3PheJRmemmwZzD3bZRpKEmFNUCgc4YhOTBizszN NHfHWWcyQDR|NEG0OS=>
KB3-1 MUHDfZRwfG:6aXOgRZN{[Xl? M1KyT|czKGh? MUPEUXNQ MXLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQMYdxNW6nZ3H0bZZmKEuELUOtNUBk\WyuczD3bZRpKEmFNUCgc4YhOi5|IN88US=> MUOxPVM6PzN{Mh?=
KBV1 NXrwVXZ3S3m2b4TvfIlkKEG|c3H5 MVm3NkBp MkDDSG1UVw>? MoPZR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVE1odHmlb4Dyc5RmcW5vZYjwdoV{e2mwZzDLRnYyKGOnbHzzJJdqfGhiSVO1NEBw\iB2LkGg{txO MofsNVk{QTd|MkK=
A375 MWLDfZRwfG:6aXOgRZN{[Xl? MYi3NkBp Mn:4SG1UVw>? M1vyVWlEPTB;NT60JO69VQ>? MV6xPVY2PDRyOB?=
RS4-11 NHfGVYFHfW6ldHnvckBCe3OjeR?= NX3NSm1oOiCq M2PIXGlvcGmkaYTpc44hd2ZiRlzUN{BifXSxcHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAxQTlizszN NYnFXHVuOTl4NUS0NFg>
RS4-11 NInNenZHfW6ldHnvckBCe3OjeR?= Mny1NkBp MUnJcohq[mm2aX;uJI9nKE[OVEOgTXRFKG23dHHueEBifXSxcHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlA{PCEQvF2= NE\O[pkyQTZ3NESwPC=>
Sf9 NHT6RWlMcW6jc3WgRZN{[Xl? NFfJbW4{OCCvaX6= MnL0TY5pcWKrdHnvckBw\iCJU2SteIFo\2WmIG\FS2ZTKGW6cILld5Nm\CC5aYToJGlEPTBib3[gNE4yQDVizszN MUexPVg2PDB3MR?=
Ba/F3 M4XOTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LxXlczKGh? NUDud4hvUUN3ME2xMlIh|ryP NES5VmczODFzN{CwOC=>
BaPTC2 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXmzWmpiPzJiaB?= NX7qUJBEUUN3ME2wMlIzKM7:TR?= M1fVWVIxOTF5MEC0
Sf9 Moq2SpVv[3Srb36gRZN{[Xl? Mkj0NUBp M4nCUWROW09? NYH5dXA2UW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDIbZMufGGpZ3XkJHJGXCCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFEvOyEQvF2= NY[zfGlXOjBzMUewNFQ>
H4 NWXtd4YzS3m2b4TvfIlkKEG|c3H5 M13FZlExKM7:TR?= NFvuU5BVd3irY3n0fUBqdiCqdX3hckBJPCClZXzsdy=> NGLQTGYzODN3MEiwOi=>
SF-539 NIHwV|dMcW6jc3WgRZN{[Xl? NYT2VIJVOzN|IN88US=> NVS2TolUPjBibXnu NWLHWpFJTE2VTx?= Mlu3TY5pcWKrdHnvckBw\iCSRFfGVoJmfGFicHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCxNk4zKM7:TR?= NIjXVZUzODRyM{ewNC=>
U251 NE\6XJRMcW6jc3WgRZN{[Xl? MXKzN|Mh|ryP M2jHUVYxKG2rbh?= MnP4SG1UVw>? NUPnSnl2UW6qaXLpeIlwdiCxZjDWSWdHWjJicHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCxPE46KM7:TR?= M1KxSlIxPDB|N{Cw
A431 NXT4eY4xU2mwYYPlJGF{e2G7 NFXGNFFKdmirYnn0bY9vKG:oIGDES2ZT[mW2YTDlfJBz\XO|ZXSge4l1cCCLQ{WwJI9nKDF{LkKg{txO MY[yNFU2QDB5Mh?=
A431 NX;MNnBFU2mwYYPlJGF{e2G7 M2ntbWlvcGmkaYTpc44hd2ZiVlXHSnIzKGW6cILld5Nm\CC5aYToJGlEPTBib3[gNVgvQSEQvF2= NFmyU40zODV3OEC3Ni=>
HepG2 NIDNRmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\yTYw4PzJiaB?= M2TJUmlEPTB;Mz64NUDPxE1? NFjMfWIzODV5MEWyOi=>
Kasumi-1 NFHybIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPjeIFJPzJiaB?= NWHKOGtmUUN3ME2wMlAyPiEQvF2= MVKyNFU4ODV{Nh?=
RS4-11 NEToS|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGW5Ulg4OiCq M1u5cGlEPTB;MTFOwG0> Mo\aNlA2PzB3Mk[=
THP1 M33TVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XiflczKGh? Mlr3TWM2OD1yLkWg{txO MU[yNFU4ODV{Nh?=
Kasumi-1 NHzGTYhHfW6ldHnvckBCe3OjeR?= MojsTY5pcWKrdHnvckBw\iClLVvpeEBifXSxcHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAyPSEQvF2= NF;ZVlMzODh|M{CzPS=>
A549 NGPs[mlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYm0UnNmOTZiaB?= MorLRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\Wyucx?= MVSyNVQ2ODR4Mx?=
HL60 M3PxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnaZY97OTZiaB?= MWjBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy| M3W3fFIyPDVyNE[z
HUVEC NWn5O3JIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fmZVE3KGh? M3zPW2lvcGmkaYTpc44hd2ZiVlXHSk1qdmS3Y3XkJINmdGxicILvcIln\XKjdHnvckB4cXSqIFnDOVAhd2ZiMj63OUDPxE1? MV6yNVQ2ODR4Mx?=
HUVEC M3PDO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXsUm8yPiCq Mo\xTY5pcWKrdHnvckBw\iCkRlfGMYlv\HWlZXSgZ4VtdCCycn;sbYZmemG2aX;uJJdqfGhiSVO1NEBw\iB2LkC0JO69VQ>? NH\vWJIzOTR3MES2Ny=>
IM9 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXuxOkBp MkHQRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSV25JINmdGy| Ml3hNlE1PTB2NkO=
K562 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nBSFE3KGh? NY\xWHg6SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gT|U3OiClZXzsdy=> NVLlW45tOjF2NUC0OlM>
MDA-MB-231 NX3CTodlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXixOkBp NY\aNpd6SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\Wyucx?= M1:1S|IyPDVyNE[z
H460 M2n2U2N6fG:2b4jpZ{BCe3OjeR?= NYfrRoc5PzJiaB?= MXvJR|UxRTJwNzFOwG0> MoexNlE3OjF6OEC=
SMMC7721 NXrqepNqS3m2b4TvfIlkKEG|c3H5 NF\XVY04OiCq NXXmOFVWUUN3ME22MlQ4KM7:TR?= MnvuNlE3OjF6OEC=
WI38 NYjJXFk1S3m2b4TvfIlkKEG|c3H5 M3XwOlczKGh? NHLGbVNKSzVyPUiuOVYh|ryP NV\1W3F{OjF4MkG4PFA>
HEK293 M{e0b2tqdmG|ZTDBd5NigQ>? NG\3VnEyODBibl2= MXKxJIg> Mmr1[I9meyCwb4SgbY5pcWKrdDDWSWdHNWmwZIXj[YQh[XW2b4Doc5NxcG:{eXzheIlwdiCxZjD0fZJwe2mwZTCxNVc2KHKnc3nkeYUhd25iVlXHSnIzKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJM> Mo\ZNlE5QDV{OEe=
HUVEC NYPLcVdUTnWwY4Tpc44hSXO|YYm= M4TqcFEh|ryP NWPYU|FFOjRiaB?= MVzBcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckBXTUeILXnu[JVk\WRiY3XscEBucWe{YYTpc44> NVnmN2hSOjF7NkOzNFU>
HUVEC NWjzUVA1TnWwY4Tpc44hSXO|YYm= NGnUNm4yKM7:TR?= NEK1dmkyKGh? MmXlTY5pcWKrdHnvckBw\iCHUlugdIhwe3Cqb4L5cIF1cW:wIHH0JHRpejJyMj;UfZIzODRiaX6gWmVITi2|dHnteYxifGWmIFjVWmVE M3K1d|IyQTZ|M{C1
HUVEC M3[2bWZ2dmO2aX;uJGF{e2G7 NYPNXZpUOSEQvF2= M3jYfFEhcA>? MYjJcohq[mm2aX;uJI9nKGWQT2OgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmei1zMUeyJIlvKF[HR1[td5RqdXWuYYTl[EBJXV[HQx?= MYGyNVk3OzNyNR?=
HUVEC Ml7NT4lv[XOnIFHzd4F6 MlTUNUDPxE1? NFfuZ3oyKGh? NV7VfIVkUW6qaXLpeIlwdiCxZjDWSWdHWjJicHjvd5Bpd3K7bHH0bY9vKGG2IIT5dk0yOTd3IHnuJHZGT0Zvc4TpcZVt[XSnZDDIWXZGSw>? NGrGXnkzOTl4M{OwOS=>
HUVEC MXHGeY5kfGmxbjDBd5NigQ>? MnfDNUDPxE1? NF3JOWwyKGh? NITCW2lld2W|IH7veEBqdmirYnn0JGFMXCCyaH;zdIhwenmuYYTpc44h[XRiU3XyMVQ4OyCrbjDWSWdHNXO2aX31cIF1\WRiSGXWSWM> MYOyNVk3OzNyNR?=
HL60 MmHVR5l1d3SxeHnjJGF{e2G7 NFLC[pI2OCEQvF2= M1;QcFQ5KGh? M2XGbGROW09? NH3VUG5KSzVyPUG1MlUh|ryP M1TBO|IzODF7MUi4
K562 MULDfZRwfG:6aXOgRZN{[Xl? MWm1NEDPxE1? MUm0PEBp M{PVWWROW09? Mof6TWM2OD1{MT65JO69VQ>? M{fPXVIzODF7MUi4
PC3 NWfKU2o{S3m2b4TvfIlkKEG|c3H5 NV[3ZpB4PTBizszN NUXaboNOPDhiaB?= NGTzNlRFVVOR MkjETWM2OD1{NT6xJO69VQ>? MmfGNlIxOTlzOEi=
SF-539 M1jVTGtqdmG|ZTDBd5NigQ>? M1nvPFM{OyEQvF2= NE\nNWE3OCCvaX6= NEXvVodKdmirYnn0bY9vKG:oIGDES2ZT[mW2YTD0fZJwe2mwZTDrbY5ie2ViYXP0bZZqfHliaX6gVGRITi2EQj3zeIlufWyjdHXkJIh2dWGwIGPGMVU{QSClZXzsd{B4cXSqIFnDOVAhd2ZiMUKuNkDPxE1? MYGyNlIxPDd2MR?=
HAEC MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\GN|ExOCEQvF2= NXTiUHpMPzJiaB?= NITtdINCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjBSWMh[2WubIOg[ZhxemW|c3nu[{BXTUeIUjD3bZRpKEmFNUCgc4YhOC5zIN88US=> MX:yNlQ1PDZ5OR?=
HT-29 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHOdIoyODBizszN M3TIVFczKGh? M17VN2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGStNlkh[2WubIOg[ZhxemW|c3nu[{BXTUeIUjD3bZRpKEmFNUCgc4YhOC5|MzFOwG0> MmL1NlI1PDR4N{m=
MV4-11 NYrL[nQ1S3m2b4TvfIlkKEG|c3H5 NXPHPGNuPzJiaB?= MkexTWM2OD1yLkCwN{DPxE1? NGG1bJAzOjR3MkWxPC=>
HepG2 MXnDfZRwfG:6aXOgRZN{[Xl? MUG0PEBp MXHJR|UxRTF|LkK0JO69VQ>? NXPEbYZqOjJ2OEO2NFg>
PC9 MlLlR5l1d3SxeHnjJGF{e2G7 MWi0PEBp NH\zOpRKSzVyPUGwMlk4KM7:TR?= MYWyNlQ5OzZyOB?=
CAKI-1 NVP2OFBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LpeVExOCEQvF2= MojMOFghcA>? Ml7NSG1UVw>? MUjHTVUxRTBwNkOg{txO M{jaRVIzPTZyNkK3
EKVX NHPXXYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XHc|ExOCEQvF2= NV3qR3VsPDhiaB?= NID0dXZFVVOR MVLHTVUxRTdwOTFOwG0> NH31N3AzOjV4ME[yOy=>
MCF7 MmH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYmxNFAh|ryP MYK0PEBp NH\EUodFVVOR NFmyTGJIUTVzPUKg{txO M1\PblIzPTZyNkK3
MDA-MB-435 NI\2S5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYCxNFAh|ryP MYO0PEBp Mlj1SG1UVw>? NFTGZW5IUTV{PUKg{txO MmnENlI2PjB4Mke=
OVCAR3 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVWxNFAh|ryP MYe0PEBp NXLhVJhPTE2VTx?= NWTEUXk4T0l3M{2zMlIh|ryP NUjRWHdPOjJ3NkC2Nlc>
SNB19 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjOW2oyODBizszN MWW0PEBp NULYSld7TE2VTx?= MoLZS2k2PD1zMDFOwG0> Mk[1NlI2PjB4Mke=
SW620 NEDCb|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmKyNVAxKM7:TR?= NU\acllYPDhiaB?= M3PKPGROW09? NFrxfJVIUTV3PUGuN{DPxE1? NGm2OWMzOjV4ME[yOy=>
TK10 NUTQNlBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX[xNFAh|ryP NXqwSJVZPDhiaB?= NYHFTlFrTE2VTx?= NHHTUm5IUTV4PU[uN{DPxE1? M{jSfVIzPTZyNkK3
UACC257 NGjJRohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPl[lMyODBizszN Mnr0OFghcA>? MX;EUXNQ NHj0OWZIUTV5PUSg{txO MmLMNlI2PjB4Mke=
HAEC MWjDfZRwfG:6aXOgRZN{[Xl? NHXKeXYyODBizszN MUG3NkBp MlHmSG1UVw>? MYrDfZRwfG:6aXPpeJkh[WejaX7zeEBXTUeIUjDlfJBz\XO|aX7nJGhCTUNid3n0bEBKSzVyIH;mJFAvOSEQvF2= MmTzNlMyOzF3NEG=
HT-29 NIL5XJdEgXSxdH;4bYMhSXO|YYm= NXnZclAyOTByIN88US=> MmXVO|IhcA>? NX64ZohDTE2VTx?= NGHYTmlEgXSxdH;4bYNqfHliYXfhbY5{fCCYRVfGVkBmgHC{ZYPzbY5oKGi3bXHuJGhVNTJ7IHPlcIx{KHerdHigTWM2OCCxZjCwMlM{KM7:TR?= NFzSN2QzOzF|MUW0NS=>
HCT116 M3ricmZ2dmO2aX;uJGF{e2G7 Ml7ONlQhcA>? M4HwWGROW09? MoDDRY51cW2rZ4LheI9zgSCjY4Tpeol1gSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHygcYloemG2aX;u NUjwb5h{OjNzNUOyNFA>
HUVEC MX7GeY5kfGmxbjDBd5NigQ>? NWXHUYk2OiEQvF2= M4K2V|E5KGh? MV;EUXNQ M3K0cmFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHnuJGhWXkWFczD1coRmeiCqeYDvfIlkKGOxbnTpeIlwdiCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHS3YnWg[o9zdWG2aX;u M4DxfVI{OTV|MkCw
ACHN MoTUR5l1d3SxeHnjJGF{e2G7 MnGzOkBl Mlq5TWM2OD1{LkWg{txO NGnveZEzOzN4MEGwOC=>
A498 NGrJOIdEgXSxdH;4bYMhSXO|YYm= NXfSdHpJOTByIN88US=> NYG1Wld1PzJiaB?= NXnZR416TE2VTx?= NYfDU2NqUUN3ME20MlMh|ryP MXSyN|Q5QTZ{Nh?=
HUVEC MkHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjybXY{KM7:TR?= M{C0d|I1KGh? MoWySG1UVw>? M3vWcmFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiVlXHSk1qdmS3Y3XkJJR2[mViZn;ycYF1cW:wIIfpeIghTUN3MDDv[kAxNjZ2NTFOwG0> MWKyN|U5OzlzMR?=
HUVEC MmT3T4lv[XOnIFHzd4F6 NUXhe4RqOjByIN88US=> MWXEUXNQ NEe5PXRKdmirYnn0bY9vKG:oIG\FS2ZTOiCyaH;zdIhwenmuYYTpc44hcW5iZ4Lve5RpKG[jY4Tvdk1{fGmvdXzheIVlKEiXVlXD NVvyWIFYOjN3OEO5NVE>
HUVEC MULLbY5ie2ViQYPzZZk> MkfoNlAxKM7:TR?= Mke5SG1UVw>? MnfjTY5pcWKrdHnvckBw\iCYRVfGVlEheGixc4Doc5J6dGG2aX;uJIlvKGe{b4f0bEBn[WO2b4Ktd5RqdXWuYYTl[EBJXV[HQx?= MVGyN|U5OzlzMR?=
A549 M2[zOGN6fG:2b4jpZ{BCe3OjeR?= NW\UfWV4PzJiaB?= MWDEUXNQ MoTqTWM2OD1{LkS0JO69VQ>? NUK0SXZKOjN4MEK0OFE>
HCT116 MnOxR5l1d3SxeHnjJGF{e2G7 MVS3NkBp MmP4SG1UVw>? Mkn5TWM2OD12LkexJO69VQ>? MVeyN|YxOjR2MR?=
MCF7 NWG2OWdzS3m2b4TvfIlkKEG|c3H5 M{j5dlczKGh? NUjvdldmTE2VTx?= M{nQZmlEPTB;Nj6yPUDPxE1? M4G4fFI{PjB{NESx
BGC Ml;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPkNnZlPzJiaB?= M2rCdmROW09? MUjJR|UxRTRwN{ig{txO MmfVNlM6QTlyNEC=
BxPC3 MoTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrFO|IhcA>? M4j3SmROW09? MWXJR|UxRTNwNkOg{txO NF\QZWozOzl7OUC0NC=>
HT-29 NF\QclZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUW3NkBp M4DheGROW09? NHGyN4pKSzVyPUGuOFch|ryP M2XEZ|I{QTl7MESw
T24 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzXS5RQPzJiaB?= MkTQSG1UVw>? M3LtTWlEPTB;Mj60OEDPxE1? MVyyN|k6QTB2MB?=
4T1 MnHZR5l1d3SxeHnjJGF{e2G7 NVnxfIVuPzJiaB?= M2LhTmROW09? NYq2U5VRUUN3ME2wMlAyPiEQvF2= M1XiZVI1QDlyNkWy
MCF7 NYDGeYlUS3m2b4TvfIlkKEG|c3H5 NXzLVXpNPzJiaB?= Mke1SG1UVw>? M{PoR2lEPTB;MD6wNlcyKM7:TR?= MYCyOFg6ODZ3Mh?=
MCF7 MV3DfZRwfG:6aXOgRZN{[Xl? NWriVGF4PzJiaB?= NWnYW|Z1TE2VTx?= MmW2TWM2OD1yLkCyPVMh|ryP NE\PT4kzPDh7ME[1Ni=>
MDA-MB-231 M1;UeGN6fG:2b4jpZ{BCe3OjeR?= Mn3qO|IhcA>? MWLEUXNQ NYjyZXpOUUN3ME2wMlAzOjNizszN MV[yOFg6ODZ3Mh?=
MDA-MB-435 MlzTR5l1d3SxeHnjJGF{e2G7 NGrhXoU4OiCq NV\zdIVuTE2VTx?= NX;uR|REUUN3ME2wMlAxQTdizszN MXOyOFg6ODZ3Mh?=
MDA-MB-468 NVLqUm1ZS3m2b4TvfIlkKEG|c3H5 MnvaO|IhcA>? NVHXTm17TE2VTx?= NInS[nNKSzVyPUCuNFA3OSEQvF2= MXSyOFg6ODZ3Mh?=
A431 M4rIbWtqdmG|ZTDBd5NigQ>? NYLsN2h5OTBizszN NUfOeXBMOSCq NYS2fm9DTE2VTx?= MojoTY5pcWKrdHnvckBw\iCHR1\SJJdqfGhiSVO1NEBw\iByLkG3NlEh|ryP NHTRXIozPDh7ME[1Ni=>
SH-SY5Y NVqzSJZ2U2mwYYPlJGF{e2G7 MWixNEDPxE1? NFHNT2oyKGh? M3rLTmROW09? MWPJcohq[mm2aX;uJI9nKFCGR1\SZoV1[SC5aYToJGlEPTBib3[gNE4xQDNzIN88US=> MXuyOFg6ODZ3Mh?=
U251 NV\kTZk2U2mwYYPlJGF{e2G7 NInuUXYyOCEQvF2= NYDwPGdqOSCq NIqxWINFVVOR NVfROnRzUW6qaXLpeIlwdiCxZjDWSWdHWjJid3n0bEBKSzVyIH;mJFAvODF6OTFOwG0> MnXBNlQ5QTB4NUK=
Bel7402 MnfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWG3NkBp NU\YUlFFTE2VTx?= MlLjTWM2OD1{Lk[3JO69VQ>? NYHrfG02OjR7MES5OlE>
HK2 NG[4TpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXX5cWR4PzJiaB?= NHLxdY1FVVOR MlfsTWM2OD13Lki1JO69VQ>? M1HjdVI1QTB2OU[x
LO2 NGf3VZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XLN|czKGh? NUXQNHc5TE2VTx?= NHP2VZRKSzVyPUG5Mlk{KM7:TR?= M1jmclI1QTB2OU[x
MV4-11 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXkOFghcA>? M3PuSmROW09? NHHYb4ZKSzVyPUCuNFA{KM7:TR?= NGXJbGszPDlyNEm2NS=>
NCI-H3122 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TRZVczKGh? NFHaOlNFVVOR MorZTWM2OD1yLkizJO69VQ>? MnjzNlQ6ODR7NkG=
NCI-H460 NYrDTFRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHuO|IhcA>? MnrVSG1UVw>? M4HpW2lEPTB;ND6zNUDPxE1? MljDNlQ6ODR7NkG=
NCI-H526 NVuzR5lWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWO3NkBp NVXOU5oxTE2VTx?= MoHlTWM2OD1zLkCxJO69VQ>? NYHJdJFMOjR7MES5OlE>
TT NY\6eWo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVy3NkBp MmDiSG1UVw>? NYjCU5NpUUN3ME2wMlA1KM7:TR?= M{TxdVI1QTB2OU[x
EoL-1-cell NXnCNGN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTkfHh{UUN3ME2xMlY1KHCP M1HtcXNCVkeHUh?=
MV-4-11 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTJ5MjDwUS=> MnTZV2FPT0WU
NOS-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHpXGg5UUN3ME2xOU4{KG6P NX\OXHA2W0GQR1XS
CGTH-W-1 M4XG[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TWZ2lEPTB;M{CuPVQhdk1? M2DhRXNCVkeHUh?=
MONO-MAC-6 MlTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LKcGlEPTB;M{OuPEBvVQ>? MnPjV2FPT0WU
ALL-PO M4PpPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTd7Lki5JI5O M3Wxb3NCVkeHUh?=
NKM-1 NX;oNnU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTl6LkWyJI5O MYrTRW5ITVJ?
KM12 MmHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEiyRo1KSzVyPUO1NE4yPCCwTR?= NIH0XoRUSU6JRWK=
TE-15 MoHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTVyNz62NUBvVQ>? MYHTRW5ITVJ?
697 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13zS2lEPTB;NkG0MlI2KG6P Mkj2V2FPT0WU
MOLT-16 MnLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXlPJZmUUN3ME22N|EvOzJibl2= M4qy[XNCVkeHUh?=
GB-1 MoPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fPOGlEPTB;N{GwMlI{KG6P NFXzd3VUSU6JRWK=
TE-12 MlfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRThyND61OUBvVQ>? NWLmVnNKW0GQR1XS
ES6 M3nDRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7qfHBqUUN3ME25PFEvODZibl2= MXPTRW5ITVJ?
LC-2-ad MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXuNo9KSzVyPUGuNVE1ODdizszN MkjSV2FPT0WU
BL-70 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTFwMUG4OFYh|ryP M2f3R3NCVkeHUh?=
ETK-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkC1TWM2OD1zLkK4OVgh|ryP NHfodnJUSU6JRWK=
A4-Fuk NGPub5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHMNVFKSzVyPUGuN|QyPDFizszN M4TGV3NCVkeHUh?=
OCI-AML2 NEiwSXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLRTWM2OD1zLkO2PFUyKM7:TR?= MmTXV2FPT0WU
SIG-M5 MmD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HnO2lEPTB;MT6zO|AxQSEQvF2= NIjBXVFUSU6JRWK=
NCI-SNU-16 NFTnW4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWqwR4pjUUN3ME2xMlQ3PDh4IN88US=> NXHtSnFMW0GQR1XS
PSN1 MoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\0OHk1UUN3ME2xMlUxPjd4IN88US=> M{fOOnNCVkeHUh?=
SR NEHPOotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETlOGVKSzVyPUGuOVQ2PzJizszN MXHTRW5ITVJ?
A3-KAW NIf3SJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHZd5lvUUN3ME2xMlYzPTR4IN88US=> MkmwV2FPT0WU
KS-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\SOWlEPTB;MT62PVI1PyEQvF2= M{DFdHNCVkeHUh?=
CTV-1 Ml3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTKdWRzUUN3ME2xMlczPzVzIN88US=> NEDqUVRUSU6JRWK=
LB1047-RCC MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnaTWM2OD1zLkixOlI1KM7:TR?= MYXTRW5ITVJ?
EMG-01 M{fr[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;CTWM2OD1zLkizOVY{KM7:TR?= MkTPV2FPT0WU
TE-11 MofXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTFwOEO5PFUh|ryP M1\4UXNCVkeHUh?=
CMK M3jCWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYe2OZIzUUN3ME2xMlk2PTF5IN88US=> MV7TRW5ITVJ?
NB1 Mm[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljPTWM2OD1zLkm2NVE4KM7:TR?= MYjTRW5ITVJ?
HAL-01 NI\PRm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXFOWtoUUN3ME2yMlA2QTR4IN88US=> NUHKW2xEW0GQR1XS
DEL Mo\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTJwMEi0PFIh|ryP NFK2VlRUSU6JRWK=
RL95-2 M3\3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLPU5FsUUN3ME2yMlEyOTN5IN88US=> Mof0V2FPT0WU
KARPAS-299 NInJTHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{f6fmlEPTB;Mj6xNVMyOyEQvF2= M3q2bHNCVkeHUh?=
EW-16 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\CZWNKSzVyPUKuNVM2ODhizszN MmDyV2FPT0WU
RS4-11 NF;id3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTJwMUe5NlQh|ryP NV7EO3VSW0GQR1XS
BB30-HNC NWP4SYJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJwMkKzO|Uh|ryP NGm1[XpUSU6JRWK=
DOHH-2 M1LSWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1npS2lEPTB;Mj6zN|Q{OSEQvF2= Mn;FV2FPT0WU
RPMI-8402 M1m4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkH5TWM2OD1{LkOzOlE5KM7:TR?= M2rnOXNCVkeHUh?=
BV-173 NXHK[Gx7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn:zTWM2OD1{LkOzOlYh|ryP NHXZeZFUSU6JRWK=
TE-10 NXjFNlZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTCVXAxUUN3ME2yMlM1Ozh2IN88US=> MnrIV2FPT0WU
TE-8 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfyR3ZKSzVyPUKuN|cxOzhizszN MnXMV2FPT0WU
K052 M1vrZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoL6TWM2OD1{LkSwNlAzKM7:TR?= NUTxTItZW0GQR1XS
KARPAS-45 NIjvZ3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTJwNEm0OFYh|ryP NHXqO4VUSU6JRWK=
SK-NEP-1 NY\u[m9QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPPTWM2OD1{Lk[wNlM4KM7:TR?= NWPtWnlFW0GQR1XS
KGN MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTJwNkCzN|kh|ryP NH3pc2VUSU6JRWK=
ML-2 NHS3WIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEO0U3RKSzVyPUKuOlM2OTJizszN MoHuV2FPT0WU
LAMA-84 MmXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zxW2lEPTB;Mj62PVU1PSEQvF2= MonoV2FPT0WU
LXF-289 M3fQUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvjOldWUUN3ME2yMlczQTh7IN88US=> NGf0VG5USU6JRWK=
A101D NFzjTG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTJwN{izNFQh|ryP NV33WGd{W0GQR1XS
KY821 NYLBXXRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojaTWM2OD1{Lke5O|U5KM7:TR?= NV\VdI9iW0GQR1XS
ES4 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3leItKSzVyPUKuPFA3OjhizszN NYf1fXVtW0GQR1XS
SCC-3 NVT2SoNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHYWHRKSzVyPUKuPFI5QTFizszN NF3XbWlUSU6JRWK=
NALM-6 M13H[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfvXVJ1UUN3ME2yMlkxPDd|IN88US=> M{H6WHNCVkeHUh?=
BL-41 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrvT2lbUUN3ME2yMlkyOjJ{IN88US=> MYXTRW5ITVJ?
OPM-2 M4TVbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTNwMEW5OVQh|ryP MVTTRW5ITVJ?
SF126 M4Ple2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDzUmJRUUN3ME2zMlA3OTl6IN88US=> NVnOVmNJW0GQR1XS
BE-13 M1\uOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2ezVWlEPTB;Mz6yN|EyOSEQvF2= M4q5bnNCVkeHUh?=
SF268 NH35co5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2e4TGlEPTB;Mz6zNlg3QSEQvF2= MoXDV2FPT0WU
MOLT-4 M3LL[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfOTZBOUUN3ME2zMlM6QDN6IN88US=> Mkj0V2FPT0WU
PF-382 M1HmOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkO2TWM2OD1|LkS0OVch|ryP NEC4VGxUSU6JRWK=
HEL NXjTe5R3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnNRo5KSzVyPUOuOFgxODVizszN MlOzV2FPT0WU
RPMI-6666 MkGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV71WGlXUUN3ME2zMlU1OTdzIN88US=> NYrHWHNYW0GQR1XS
QIMR-WIL NV\MNllJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moe1TWM2OD1|Lk[zN|kyKM7:TR?= MX3TRW5ITVJ?
ATN-1 NGHWeVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\hXZNKSzVyPUOuOlcyOTRizszN NEG5UItUSU6JRWK=
BB49-HNC NVjHeHc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;PcpNVUUN3ME2zMlcxPTB6IN88US=> NHPjVItUSU6JRWK=
HCE-4 NUDSTXY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYm0[ZZ{UUN3ME2zMlc5PjR{IN88US=> M{\GZXNCVkeHUh?=
SK-LMS-1 M2r2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEP0fnVKSzVyPUOuPFM{OzhizszN MmPYV2FPT0WU
MS-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TRWmlEPTB;Mz64N|c4QCEQvF2= M{TDdHNCVkeHUh?=
JAR NWq0S45zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTNwOUi4N|Ih|ryP M2nRe3NCVkeHUh?=
KE-37 NXv6c4VpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTRwME[xOVgh|ryP NYLWZ3IzW0GQR1XS
LB996-RCC MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTRwMUKxOlgh|ryP MVTTRW5ITVJ?
HH M{HWR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUiwc3FwUUN3ME20MlIxQTF2IN88US=> MUTTRW5ITVJ?
HL-60 NV3hfZhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13ZTWlEPTB;ND6yNVA3PSEQvF2= MYfTRW5ITVJ?
HOP-62 MnThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3v3e2lEPTB;ND6zN|UzKM7:TR?= M1L0[3NCVkeHUh?=
NOMO-1 NH22VG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2CwemlEPTB;ND6zN|Y6QSEQvF2= MXjTRW5ITVJ?
DU-4475 NHzydGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTRwM{[3Nlkh|ryP M3XZR3NCVkeHUh?=
LC4-1 M{LmZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXX3OZZKUUN3ME20MlM5ODdizszN NIPSZ2hUSU6JRWK=
MC116 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPZWnpKSzVyPUSuOFMxQDFizszN NVHvPVB6W0GQR1XS
SW982 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWqzfHlbUUN3ME20MlU2OzB5IN88US=> NGHRSHNUSU6JRWK=
SK-N-DZ MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDMTWM2OD12Lk[3NFk6KM7:TR?= M1;iRXNCVkeHUh?=
EW-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX63XYZXUUN3ME20MlY4QTFzIN88US=> NHPGRoJUSU6JRWK=
SU-DHL-1 NU[0O5hiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;WS2lEPTB;ND64NFE4PCEQvF2= MlLLV2FPT0WU
L-363 M{Lp[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\1Sol1UUN3ME20MlgxPjJzIN88US=> MmXEV2FPT0WU
OS-RC-2 M3XHOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWC5d5g4UUN3ME20Mlg4OzFizszN NUDjfpRJW0GQR1XS
HD-MY-Z NY\zc5VGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPmdGVKSzVyPUWuNVc{ODFizszN M3rnWnNCVkeHUh?=
MHH-PREB-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPFTWM2OD13LkOyN|EzKM7:TR?= M{PkbnNCVkeHUh?=
HC-1 NG\3WnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTVwNEOyPVEh|ryP M3G3PHNCVkeHUh?=
SK-MM-2 Mn;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTVwNEe4NkDPxE1? MmXoV2FPT0WU
SH-4 M1ntcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\tN|lKSzVyPUWuOFg{PyEQvF2= MV;TRW5ITVJ?
MHH-CALL-2 M4TKcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnJTWM2OD13Lke2O|E6KM7:TR?= NVHwSmlmW0GQR1XS
KG-1 MmniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XnfWlEPTB;Nj6wNlg4QCEQvF2= NIT6TY1USU6JRWK=
J-RT3-T3-5 M{nVNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3SybmlEPTB;Nj6wO|kxQSEQvF2= MoK2V2FPT0WU
MMAC-SF MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTZwMUC5OFkh|ryP MUPTRW5ITVJ?
IST-SL2 M2HNemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTZwMUK1NVkh|ryP MVXTRW5ITVJ?
SW954 NHLRNVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4H4UGlEPTB;Nj6yO|UyPyEQvF2= MVzTRW5ITVJ?
HDLM-2 NUK3U45LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\iTWM2OD14LkOyNVA6KM7:TR?= MnHkV2FPT0WU
ST486 NVX6SoxiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3jS4oxUUN3ME22MlM1PzFizszN NY\D[lN{W0GQR1XS
DG-75 M2DUfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\GTWM2OD14LkSzNFY6KM7:TR?= NFTRN|dUSU6JRWK=
EW-3 NGLDU2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmX2TWM2OD14LkSzNlA4KM7:TR?= NX3Pfog3W0GQR1XS
8-MG-BA NXr3dJk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjPb5VjUUN3ME22MlUyPTB5IN88US=> NF;Hb2VUSU6JRWK=
GT3TKB NG\X[FRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorxTWM2OD14Lk[wO|Y{KM7:TR?= NFqzbZpUSU6JRWK=
KU812 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PLNmlEPTB;Nj62PVQzKM7:TR?= M1rPXHNCVkeHUh?=
CESS NVH2cYFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTdwMUC0N|gh|ryP MWLTRW5ITVJ?
BC-1 M4PFXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXyTWM2OD15LkK0PFEzKM7:TR?= M1jLbnNCVkeHUh?=
MZ1-PC MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjkcYZKSzVyPUeuN|A{QDlizszN MmXnV2FPT0WU
NCI-H82 MkK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LZRWlEPTB;Nz6zO|g2KM7:TR?= M1y4WHNCVkeHUh?=
NCI-H1355 NHvVVIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTdwNEW4NFQh|ryP NEPpTVlUSU6JRWK=
RPMI-8226 M3\IeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTdwNUC3N|kh|ryP NILhXVVUSU6JRWK=
ARH-77 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13PSmlEPTB;Nz61N|U6PyEQvF2= NGLPUW5USU6JRWK=
MN-60 NUXJ[mNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XMWGlEPTB;Nz61OFA5QCEQvF2= NX3CRZhLW0GQR1XS
IMR-5 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnyT25KSzVyPUewOVQ5PzZizszN NFLHV3NUSU6JRWK=
KARPAS-422 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjHXnFKSzVyPUeuOVczODZizszN Mn\YV2FPT0WU
CA46 MlPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTdwNUiwNVIh|ryP M2Xl[XNCVkeHUh?=
SJSA-1 NXq4[FVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\jTWM2OD15Lk[2NFYyKM7:TR?= MWnTRW5ITVJ?
no-11 NX;PPGhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjVe49IUUN3ME23Mlc4PTV5IN88US=> NH;1cWlUSU6JRWK=
IST-SL1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHDfI9KSzVyPUiuNFI1OTdizszN NXvGRWZiW0GQR1XS
NCI-H209 NF:wToZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVf5b4g2UUN3ME24MlEyPjV{IN88US=> M{\3[XNCVkeHUh?=
TALL-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3odlBEUUN3ME24MlE5Ozh2IN88US=> Mmf3V2FPT0WU
KMOE-2 M{[4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3ntS2lEPTB;OD6xPVQzKM7:TR?= M4TISnNCVkeHUh?=
HCC1599 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;rcpZwUUN3ME24MlE6QTh5IN88US=> MknVV2FPT0WU
CI-1 M4jUdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnf3TWM2OD16LkKwOFEyKM7:TR?= NHvzfFZUSU6JRWK=
NCI-H1304 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TrTGlEPTB;OD6yNFY3OSEQvF2= M2q2enNCVkeHUh?=
Daudi NXi3Z4hFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnYOXVmUUN3ME24MlI{PTR4IN88US=> NF7TN|RUSU6JRWK=
CPC-N NVP1W|ZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRThwMkmxPVkh|ryP MV;TRW5ITVJ?
MC-CAR NGO3e3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRThwM{O1PEDPxE1? NGXIPZJUSU6JRWK=
SW872 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7BbZJUUUN3ME24MlM1PzV6IN88US=> NIG2WoNUSU6JRWK=
OVCAR-4 NIm3VZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXzTWM2OD16LkWwN|UyKM7:TR?= NYPjTYlXW0GQR1XS
OCUB-M MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPubIlKSzVyPUiuOVY2ODhizszN MVPTRW5ITVJ?
SK-PN-DW MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2f2[mlEPTB;OD62NFk5PSEQvF2= NHH6fYdUSU6JRWK=
NCCIT MlPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkf3TWM2OD16LkexO|Q2KM7:TR?= MkjEV2FPT0WU
NCI-H1648 MlnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1r4bGlEPTB;OT6xN|g{PCEQvF2= MYPTRW5ITVJ?
COR-L279 NV;HcG9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTlwM{mwPUDPxE1? MnH5V2FPT0WU
LS-123 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjkTWM2OD17Lk[4NVYyKM7:TR?= NES3U2FUSU6JRWK=
LP-1 Mlq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTlwN{iwPFMh|ryP NGnNXY5USU6JRWK=
NB13 NH30V4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnOfohYUUN3ME25Mlc6QTl2IN88US=> MkTnV2FPT0WU
ONS-76 M4nKZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HHVWlEPTB;OT64NVAyPiEQvF2= MX3TRW5ITVJ?
VA-ES-BJ M3fNTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTlwOUm5N|Mh|ryP M2PobXNCVkeHUh?=
GR-ST M4L6OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHW5XIZKSzVyPUGwMlIzODdizszN NFnjRmxUSU6JRWK=
ES1 M1W0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moi0TWM2OD1zMD6yPVg1KM7:TR?= M3LFbXNCVkeHUh?=
NB14 NH;hZXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\BT2R7UUN3ME2xNE46Ojd5IN88US=> NXLwVHFrW0GQR1XS
Ramos-2G6-4C10 MnO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTKTWM2OD1zMT6yOlUh|ryP NFzwRYNUSU6JRWK=
RXF393 NHfvbHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TXe2lEPTB;MUGuOFg{PCEQvF2= NEjDWohUSU6JRWK=
NCI-H2107 M3vlcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXBTWM2OD1zMT61PVg1KM7:TR?= MljjV2FPT0WU
K562 MnXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjMcVFSUUN3ME2xNU45PzB{IN88US=> M{m5cnNCVkeHUh?=
LOUCY NHnRNnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33aVWlEPTB;MUGuPVg4PSEQvF2= Ml7OV2FPT0WU
TGBC1TKB NVm1PGtxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LBdmlEPTB;MUKuNFAzKM7:TR?= NXfnfJNWW0GQR1XS
COLO-320-HSR NH\ZXHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrqTWM2OD1zMj6xOVY2KM7:TR?= NITub5ZUSU6JRWK=
K5 NEfPTHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTF{LkK5PFUh|ryP MXTTRW5ITVJ?
BC-3 M1nVTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[2[5ZrUUN3ME2xNk41PjVzIN88US=> NITDb4xUSU6JRWK=
REH NWLaZ4ZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDHNZR4UUN3ME2xNk43PDl6IN88US=> Mn:xV2FPT0WU
NEC8 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4D1SGlEPTB;MUKuOlg5PyEQvF2= NF6zZZBUSU6JRWK=
IST-MEL1 NXPtcIFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXe3RoxEUUN3ME2xNk45Pjl2IN88US=> NX3pb2d{W0GQR1XS
NCI-H128 NHj6NIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jUVWlEPTB;MUOuNFczOyEQvF2= NVrzdmVyW0GQR1XS
NCI-H1694 Mk\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvaN2dbUUN3ME2xN{4yOTR2IN88US=> MYXTRW5ITVJ?
TGW NFjpPG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4qyT2lEPTB;MUOuN|I4PiEQvF2= MoPpV2FPT0WU
NCI-SNU-1 M2q1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnpTnd5UUN3ME2xN{4{PDVizszN M4XBS3NCVkeHUh?=
IST-MES1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTF|Lk[3Nlkh|ryP NVLo[Io1W0GQR1XS
CTB-1 NIDmWXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTF|LkeyPVQh|ryP M{fIOXNCVkeHUh?=
HUTU-80 NUnOU3VzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTF|Lke1O|Mh|ryP MVzTRW5ITVJ?
LAN-6 Ml35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTF2LkK0OVch|ryP MlnuV2FPT0WU
KP-N-YS MnO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrNdlR6UUN3ME2xOE4zQDl2IN88US=> NUf6b41GW0GQR1XS
CCRF-CEM MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{CyfGlEPTB;MUSuOFE3QSEQvF2= NFrIUolUSU6JRWK=
NCI-H1770 M{e2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jhRmlEPTB;MUSuOVM3QSEQvF2= NGCyO3VUSU6JRWK=
MZ2-MEL NH\kNIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnkTWM2OD1zNT6yNlUyKM7:TR?= M3vTW3NCVkeHUh?=
COR-L88 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NESyU45KSzVyPUG2MlAxOTJizszN M4fwfHNCVkeHUh?=
LOXIMVI NUHETVFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTF4LkK1OkDPxE1? NF7YPIZUSU6JRWK=
KALS-1 NUDxTmFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTF4LkW5N|Eh|ryP MYLTRW5ITVJ?
D-283MED MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFW4fnhKSzVyPUG2Mlg1QDlizszN MoXEV2FPT0WU
NCI-H719 MmexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjkTWM2OD1zNj65NVYyKM7:TR?= MlXFV2FPT0WU
MLMA NFHBUFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrqV5FKSzVyPUG2Mlk6ODdizszN Mn:zV2FPT0WU
EVSA-T Mn;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTF5LkC0PFUh|ryP NEL2NIZUSU6JRWK=
SK-N-FI MnLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTF5Lk[5NVMh|ryP NITlPHdUSU6JRWK=
NTERA-S-cl-D1 MnjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1[4dWlEPTB;MUeuPFU4OiEQvF2= NHXySGxUSU6JRWK=
NCI-H1882 NW\q[m1jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXufXJKSzVyPUG3Mlk5OzRizszN MmDwV2FPT0WU
A704 NYG1[lFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DDcmlEPTB;MUeuPVkxPCEQvF2= M2DmUnNCVkeHUh?=
L-428 NH;BdFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjUOlRWUUN3ME2xPE4xOTVzIN88US=> M4nUNnNCVkeHUh?=
HCC1187 M2\sXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrMTZRoUUN3ME2xPE4xOTh5IN88US=> Mom0V2FPT0WU
NCI-H1581 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nUVGlEPTB;MUiuNFg3PiEQvF2= MlPjV2FPT0WU
BB65-RCC NHThSohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofaTWM2OD1zOD60NVYzKM7:TR?= NUPkUYNXW0GQR1XS
EM-2 NFO5OoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTtTWM2OD1zOD61OlczKM7:TR?= MUHTRW5ITVJ?
Raji M{foRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljFTWM2OD1zOT65OVY2KM7:TR?= MnfkV2FPT0WU
TE-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rs[GlEPTB;MkCuOFExPCEQvF2= NE\MNFVUSU6JRWK=
SW962 MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHyTWM2OD1{MD60Nlk{KM7:TR?= MWPTRW5ITVJ?
MHH-NB-11 M3XZOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrkWXVKSzVyPUKwMlU2OjFizszN NI\NTplUSU6JRWK=
no-10 NXXETlR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnHeYlIUUN3ME2yNU4xOjZ2IN88US=> MUfTRW5ITVJ?
GDM-1 M3vhS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPMTWM2OD1{MT65OFE1KM7:TR?= NUGwZmRbW0GQR1XS
KMS-12-PE MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH65bnJKSzVyPUKyMlI4PCEQvF2= MXnTRW5ITVJ?
NCI-H510A MoPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPxTWM2OD1{ND6xNlc5KM7:TR?= MX\TRW5ITVJ?
ES5 MniyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmCxTWM2OD1{ND63N|Q6KM7:TR?= MknSV2FPT0WU
JiyoyeP-2003 NF3XdHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3G3Z2lEPTB;Mk[uNlc1OiEQvF2= NWj6SmFTW0GQR1XS
NMC-G1 NF;KZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWD4eJhJUUN3ME2yO{4yQDJ{IN88US=> NWfDTXBUW0GQR1XS
NCI-H446 NF6wUo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PTS2lEPTB;MkeuOFk1PiEQvF2= NWPZNGU1W0GQR1XS
NB7 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\LemlEPTB;MkeuPVIzQSEQvF2= MVjTRW5ITVJ?
A388 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\VSpdiUUN3ME2yPE4xODd2IN88US=> NHzy[I1USU6JRWK=
JVM-2 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTjTWM2OD1{OD6yPFk5KM7:TR?= M1zuT3NCVkeHUh?=
HT-144 M1HYd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVT6NGI4UUN3ME2yPE43QSEQvF2= NH64fmtUSU6JRWK=
NCI-H747 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTJ6LkmxPVUh|ryP MkTsV2FPT0WU
NCI-H1650 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrHTWM2OD1{OT6wNVc3KM7:TR?= NYfW[lVGW0GQR1XS
EB-3 M3LOcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTJ7LkWzNFkh|ryP M3[3b3NCVkeHUh?=
KLE NXy5c3VsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7mNHVZUUN3ME2yPU43OTlizszN MXXTRW5ITVJ?
TK10 Ml;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\NfndKSzVyPUOwMlEzPiEQvF2= NHfMe4VUSU6JRWK=
COLO-668 M2jpWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTNyLke5NkDPxE1? NIT0VHhUSU6JRWK=
NCI-H23 NGHyfZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnP3TWM2OD1|MT6xNFY{KM7:TR?= MVzTRW5ITVJ?
GOTO NU\rdld6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXjTWM2OD1|MT62NFg2KM7:TR?= NYHtbJJuW0GQR1XS
MSTO-211H NYn5b|ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PjeWlEPTB;M{GuPFY4QCEQvF2= M1TLSHNCVkeHUh?=
LB831-BLC NXe3PJhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfHboFlUUN3ME2zNk4{QDR|IN88US=> MnPhV2FPT0WU
SCH MoS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTN{Lki0PFUh|ryP NH;rVnNUSU6JRWK=
EHEB MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{T1NmlEPTB;M{SuNVE6OyEQvF2= MoP4V2FPT0WU
U-266 M{S2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\HTWM2OD1|ND6yO|gyKM7:TR?= M2HROHNCVkeHUh?=
EW-11 M3fkNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XGfmlEPTB;M{SuOFczPSEQvF2= M3ThfHNCVkeHUh?=
TE-9 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnJ[ZpJUUN3ME2zO{4xPDBzIN88US=> M2DOSXNCVkeHUh?=
ES3 MnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvCTWM2OD1|Nz61NFA1KM7:TR?= MmXtV2FPT0WU
NCI-H2141 MkTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTuWFVKSzVyPUO4MlA5PDNizszN MmXUV2FPT0WU
MPP-89 NGTNfHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrtTWM2OD12Mj6wOVg3KM7:TR?= M3HGc3NCVkeHUh?=
SK-MEL-2 MkGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTR{Lk[0NFUh|ryP MWnTRW5ITVJ?
LC-1F NH[4ZXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWX6dYV3UUN3ME20N{4{Pjh{IN88US=> MoD4V2FPT0WU
NH-12 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XMd2lEPTB;NEOuPVM2QSEQvF2= MUPTRW5ITVJ?
RKO MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHoTWM2OD12ND6xNlUzKM7:TR?= M372WnNCVkeHUh?=
KM-H2 Mlm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHaTWM2OD12ND65OVc4KM7:TR?= MkHGV2FPT0WU
SK-UT-1 M3z2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnhTWM2OD12OT64PFI2KM7:TR?= NV;TfoFsW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Consistent with the substantial and selective inhibition of VEGFR2 or PDGFR phosphorylation and signaling in vivo, Sunitinib (20-80 mg/kg/day) exhibits broad and potent dose-dependent anti-tumor activity against a variety of tumor xenograft models including HT-29, A431, Colo205, H-460, SF763T, C6, A375, or MDA-MB-435. Sunitinib dosing at 80 mg/kg/day for 21 days leads to complete tumor regression in six of eight mice, without tumor re-growing during a 110-day observation period after the end of treatment. Second round of treatment with Sunitinib remains efficacious against tumors that are not fully regressed during the first round of treatment. Sunitinib treatment results in significant decrease in tumor MVD, with ~40% reduction in SF763T glioma tumors. SU11248 treatment results in a complete inhibition of additional tumor growth of luciferase-expressing PC-3M xenografts, despite no reduction in tumor size. [2] Sunitinib treatment (20 mg/kg/day) dramatically suppresses the growth subcutaneous MV4;11 (FLT3-ITD) xenografts and prolongs survival in the FLT3-ITD bone marrow engraftment model. [3]

Protocol

Kinase Assay:[1]
+ Expand

Biochemical Tyrosine Kinase Assays:

IC50 values for Sunitinib against VEGFR2 (Flk-1) and PDGFRβ are determined using glutathione S-transferasefusion proteins containing the complete cytoplasmic domain of the RTK. Biochemical tyrosine kinase assays to quantitate the trans-phosphorylation activity of VEGFR2 (Flk-1) and PDGFRβ are performed in 96-well microtiter plates precoated (20 μg/well in PBS; incubated overnight at 4 °C) with the peptide substrate poly-Glu,Tyr (4:1). Excess protein binding sites are blocked with the addition of 1-5% (w/v) BSA in PBS. Purified GST-fusion proteins are produced in baculovirus-infected insect cells. GST-VEGFR2 and GST-PDGFRβ are then added to the microtiter wells in 2 × concentration kinase dilution buffer consisting of 100 mM HEPES, 50 mM NaCl, 40 μM NaVO4, and 0.02% (w/v) BSA. The final enzyme concentration for GST-VEGFR2 or GST-PDGFRβ is 50 ng/mL. Twenty-five μL of diluted Sunitinib are subsequently added to each reaction well to produce a range of inhibitor concentrations appropriate for each enzyme. The kinase reaction is initiated by the addition of different concentrations of ATP in a solution of MnCl2 so that the final ATP concentrations spanned the Km for the enzyme, and the final concentration of MnCl2 is 10 mM. The plates are incubated for 5-15 minutes at room temperature before stopping the reaction with the addition of EDTA. The plates are then washed three times with TBST. Rabbit polyclonal antiphosphotyrosine antisera are added to the wells at a 1:10,000 dilution in TBST containing 0.5% (w/v) BSA, 0.025% (w/v) nonfat dry milk, and 100 μM NaVO4 and incubated for 1 hour at 37 °C. The plates are then washed three times with TBST, followed by the addition of goat antirabbit antisera conjugated with horseradish peroxidase (1:10,000 dilution in TBST). The plates are incubated for 1 hour at 37 °C and then washed three times with TBST. The amount of phosphotyrosine in each well is quantitated after the addition of 2,2′-azino-di-[3-ethylbenzthiazoline sulfonate] as substrate.
Cell Research:[3]
+ Expand
  • Cell lines: RS4;11, MV4;11, and OC1-AML5
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24 and 48 hours
  • Method: Cells are starved overnight in medium containing 0.1% FBS prior to addition of Sunitinib and FL (50 ng/mL; FLT3-WT cells only). Proliferation is measured after 48 hours of culture using the Alamar Blue assay or trypan blue cell viability assays. Apoptosis is measured 24 hours after Sunitinib addition by Western blotting to detect cleavage of poly (ADP-ribose) polymerase (PARP) or levels of caspase-3.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Female nu/nu mice implanted s.c. with HT-29, A431, Colo205, H-460, SF763T, C6, A375, or MDA-MB-435, and male nu/nu mice bearing luciferase-expressing PC-3M tumors
  • Formulation: Formulated as a carboxymethyl cellulose suspension or as a citrate buffered (pH 3.5) solution
  • Dosages: ~80 mg/kg
  • Administration: Orally once daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 15 mg/mL (28.16 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
In vivo Add solvents individually and in order:
4% DMSO+30% PEG 300+ddH2O
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 532.56
Formula

C22H27FN4O2.C4H6O5

CAS No. 341031-54-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02761057 Recruiting Recurrent Renal Cell Carcinoma|Stage III Renal Cell Cancer|Stage IV Renal Cell Cancer|Type 1 Papillary Renal Cell Carcinoma|Type 2 Papillary Renal Cell Carcinoma National Cancer Institute (NCI) April 2016 Phase 2
NCT02779283 Recruiting Untreated Adult Acute Myeloid Leukemia OHSU Knight Cancer Institute|National Cancer Institute (NCI) December 2015 Phase 1
NCT02626754 Enrolling by invitation Renal Cell Carcinoma vghtpe user|Taipei Veterans General Hospital, Taiwan August 2015 Phase 2
NCT02465060 Recruiting Advanced Malignant Neoplasm|Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Solid Neoplasm|Refractory Malignant Neoplasm|Refractory Plasma Cell Myeloma National Cancer Institute (NCI) August 2015 Phase 2
NCT01835158 Active, not recruiting Clear Cell Renal Cell Carcinoma|Metastatic Renal Cell Cancer|Stage III Renal Cell Cancer|Stage IV Renal Cell Cancer National Cancer Institute (NCI) July 2013 Phase 2
NCT01740154 Terminated Fatigue|Recurrent Renal Cell Cancer|Stage IV Renal Cell Cancer Case Comprehensive Cancer Center|National Cancer Institute (NCI) September 2012 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PDGFR Signaling Pathway Map

PDGFR Inhibitors with Unique Features

Related PDGFR Products

Tags: buy Sunitinib Malate | Sunitinib Malate supplier | purchase Sunitinib Malate | Sunitinib Malate cost | Sunitinib Malate manufacturer | order Sunitinib Malate | Sunitinib Malate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID